Response to letter re: Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers

被引：0
|
作者：
Blay, J. -y. [1 ,2 ,3 ]
Brahmi, M. [1 ,2 ,3 ]
Dufresne, A. [1 ,2 ,3 ]
Heudel, P. [1 ,2 ]
机构：
[1] Ctr Leon Berard, Lyon, France
[2] Univ Claude Bernard Lyon I, Lyon, France
[3] Ctr Rech Cancerol Lyon, Equipe 4, Lyon, France
来源：
ESMO OPEN | 2025年 / 10卷 / 04期
关键词：
INTERLEUKIN-6;
D O I：
10.1016/j.esmoop.2025.104531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 29 条
  • [21] Regulatory T Cell (Treg) and Cytokine Levels Post-Tocilizumab (TCZ, Anti-IL-6R) Desensitization (DES) in HLA-Sensitized Patients (HS Pts).
    Shin, B.
    Ge, S.
    Karasyov, A.
    Watanabe, J.
    Choi, J.
    Lovato, D.
    Vo, A.
    Jordan, S.
    Toyoda, M.
    TRANSPLANTATION, 2014, 98 : 115 - 115
  • [22] A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
    Dijkgraaf, E. M.
    Santegoets, S. J. A. M.
    Reyners, A. K. L.
    Goedemans, R.
    Wouters, M. C. A.
    Kenter, G. G.
    van Erkel, A. R.
    van Poelgeest, M. I. E.
    Nijman, H. W.
    van der Hoeven, J. J. M.
    Welters, M. J. P.
    van der Burg, S. H.
    Kroep, J. R.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2141 - 2149
  • [23] The increase of CD56 high NK cells and activated Treg-cells in patient with neuromyelitis optica after treatment with anti-IL-6R antibody tocilizumab
    Matsuoka, T.
    Chiba, A.
    Aranami, T.
    Nakamura, M.
    Sato, W.
    Miyake, S.
    Yamamura, T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 347 - 347
  • [24] Regulatory T Cell (Treg) and Cytokine Levels Post-Tocilizumab (TCZ, Anti-IL-6R) Desensitization (DES) in HLA-Sensitized Patients (HS Pts).
    Shin, B.
    Ge, S.
    Karasyov, A.
    Watanabe, J.
    Choi, J.
    Lovato, D.
    Vo, A.
    Jordan, S.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 115 - 115
  • [25] A Xenograft Model of Lymphocyte-Independent, Effector-Driven Macrophage Activation SyndRome Amenable to Anti-CD33 and Anti-IL-6R Treatment
    Wunderlich, Mark
    Stockman, Courtney
    Devarajan, Mahima
    Ravishankar, Navin
    Sexton, Christina
    Kumar, Ashish R.
    Mizukawa, Benjamin
    Mulloy, James C.
    BLOOD, 2016, 128 (22)
  • [26] Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG plus Rituximab
    Vo, A.
    Choi, J.
    Kim, I.
    Kahwaji, J.
    Peng, A.
    Villicana, R.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [27] Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab
    Sivapalaratnam, Suthesh
    Linpower, Lisa
    Sirigireddy, Bala
    Agapidou, Alexandra
    Jain, Susan
    Win, Nay
    Tsitsikas, Dimitris A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (06) : E212 - E214
  • [28] Spontaneous and Allo-Antibody (Ab)-Stimulated IFNγ Production in NK Cells as Detected By Cytokine Flow Cytometry (Allo-CFC) Decreased in HLA-Sensitized Kidney Transplant Patients (HS Tx Pts) Desensitized With Tocilizumab (TCZ, Anti-IL-6R)+Intravenous Immunoglobulin (IVIG)
    Ge, S.
    Shin, B.
    Lovato, D.
    Karasyov, A.
    Jordan, S.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 895 - 895
  • [29] Spontaneous and Allo-Antibody (Ab)-Stimulated IFNγ Production in NK Cells as Detected By Cytokine Flow Cytometry (Allo-CFC) Decreased in HLA-Sensitized Kidney Transplant Patients (HS Tx Pts) Desensitized With Tocilizumab (TCZ, Anti-IL-6R)+ Intravenous Immunoglobulin (IVIG).
    Ge, S.
    Shin, B.
    Lovato, D.
    Karasyov, A.
    Jordan, S.
    Toyoda, M.
    TRANSPLANTATION, 2014, 98 : 895 - 895
123